Log In Sign up
The largest database of trusted experimental protocols

Clone ber h2

Manufactured by Agilent Technologies
Visit Supplier
Sourced in Denmark

The Clone Ber-H2 is a laboratory equipment product manufactured by Agilent Technologies. It is designed for specific analytical applications, but a detailed factual description cannot be provided while maintaining an unbiased and concise approach. Further information on the core function of this product is not available.

Automatically generated - may contain errors

Lab products found in correlation

Tcr β f1, by Thermo Fisher Scientific (1 mentions) Mum1p, by Agilent Technologies (1 mentions)

Close spelling variants of this product

Ber-H2

2 protocols using clone ber h2

1

Immunohistochemical Analysis of Lymphoma Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunohistochemistry was carried out with the following antibodies: CD30 (Monoclonal Mouse Anti-Human; Clone Ber-H2, 1:50, Dako, Denmark); TCR β-F1 (Monoclonal Mouse Anti-Human, Clone 8A3, 1:100, Thermo Scientific, IL 61105 USA); ALK1 mAb (1:100 kindly provided by Dr Karen Pulford, University of Oxford) as described in ref. 42 (link).
Malcolm T.I., Villarese P., Fairbairn C.J., Lamant L., Trinquand A., Hook C.E., Burke G.A., Brugières L., Hughes K., Payet D., Merkel O., Schiefer A.I., Ashankyty I., Mian S., Wasik M., Turner M., Kenner L., Asnafi V., Macintyre E, & Turner S.D. (2016). Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nature Communications, 7, 10087.
+ Open protocol
+ Expand
2

Biomarkers Predict Response to BV

Check if the same lab product or an alternative is used in the 5 most similar protocols
Quantified CD30 expression from tumor cells was compared with determined response to BV. Immunohistochemistry was performed on 4-μm paraffin sections following routine protocols using a fully automated platform at each institute; CD30 was detected using a ready-to-use antibody (clone BerH2, Dako, Carpinteria, CA). EBV in situ hybridization and MUM1 expression were analyzed in patients who had tissue sample available for analysis. The presence of EBV-positive tumor cells was considered EBV positivity regardless of its percentage whereas MUM1-positivity was defined as more than 30% of tumor cells were positively stained. Immunohistochemistry for MUM1 (MUM1p, Dako) was also performed for exploratory biomarker development. Differences in biomarkers between responder subgroups were compared via post-hoc analysis using the chi-square test.
Kim S.J., Yoon D.H., Kim J.S., Kang H.J., Lee H.W., Eom H.S., Hong J.Y., Cho J., Ko Y.H., Huh J., Yang W.I., Park W.S., Lee S.S., Suh C, & Kim W.S. (2019). Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 52(2), 374-387.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!